Autologous stem cell transplantation in elderly patients with multiple myeloma in Korea: the KMM1807 study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jung, Jongheon | - |
dc.contributor.author | Choi, Yoon Seok | - |
dc.contributor.author | Lee, Jae Hoon | - |
dc.contributor.author | Lee, Won Sik | - |
dc.contributor.author | Kim, Sung-hyun | - |
dc.contributor.author | Park, Yong | - |
dc.contributor.author | Lee, Seung-Shin | - |
dc.contributor.author | Do, Young Rok | - |
dc.contributor.author | Jo, Jae-Cheol | - |
dc.contributor.author | Lee, Je-Jung | - |
dc.contributor.author | Kim, Jin Seok | - |
dc.contributor.author | Shin, Ho-Jin | - |
dc.contributor.author | Shin, Dong-Yeop | - |
dc.contributor.author | Yoon, Sung-Soo | - |
dc.contributor.author | Min, Chang-Ki | - |
dc.contributor.author | Kim, Kihyun | - |
dc.contributor.author | Eom, Hyeon-Seok | - |
dc.date.accessioned | 2021-08-30T19:51:09Z | - |
dc.date.available | 2021-08-30T19:51:09Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2020-07 | - |
dc.identifier.issn | 0925-5710 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/54502 | - |
dc.description.abstract | Autologous stem cell transplantation (ASCT) is not frequently performed for elderly patients multiple myeloma (MM) in Korea, despite its being a standardized approach for young patients. Medical records of 150 patients from 15 Korean institutions who received ASCT at age >= 64 years were analyzed retrospectively. Patients included had symptomatic MM, and had received their first ASCT at age >= 64 following induction chemotherapy. The main outcome was the response after ASCT. Overall survival (OS) and progression-free survival (PFS) were also analyzed. Median time to ASCT was 6.3 months. Complete response plus stringent complete response rate increased from 36 (24.0%) to 105 (70.0%) after ASCT, and high-quality response (>= very good partial response) increased from 96 (64.0%) to 125 (83.3%). With a median follow-up of 32.6 months after ASCT, 5-year OS and PFS were 59.7% and 22.8%, respectively. Febrile neutropenia occurred in 43.5%, and nausea (21.3%) and stomatitis (13.2%) were common grade 3-4 non-hematologic adverse events. Of 44 deaths, disease progression (n = 23) was the most common cause of mortality, followed by infection (n = 13). Treatment-related death occurred in four cases (2.7%). ASCT is an effective and safe option for elderly MM patients and is associated with superior clinical outcomes. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER JAPAN KK | - |
dc.subject | INTERNATIONAL STAGING SYSTEM | - |
dc.subject | MELPHALAN 200 MG/M(2) | - |
dc.subject | HIGH-DOSE MELPHALAN | - |
dc.subject | CONDITIONING REGIMENS | - |
dc.subject | DEXAMETHASONE | - |
dc.subject | LENALIDOMIDE | - |
dc.subject | DARATUMUMAB | - |
dc.subject | EFFICACY | - |
dc.subject | SAFETY | - |
dc.subject | OLDER | - |
dc.title | Autologous stem cell transplantation in elderly patients with multiple myeloma in Korea: the KMM1807 study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Yong | - |
dc.identifier.doi | 10.1007/s12185-020-02869-y | - |
dc.identifier.scopusid | 2-s2.0-85085288366 | - |
dc.identifier.wosid | 000535147900001 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF HEMATOLOGY, v.112, no.1, pp.84 - 95 | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF HEMATOLOGY | - |
dc.citation.title | INTERNATIONAL JOURNAL OF HEMATOLOGY | - |
dc.citation.volume | 112 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 84 | - |
dc.citation.endPage | 95 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.subject.keywordPlus | INTERNATIONAL STAGING SYSTEM | - |
dc.subject.keywordPlus | MELPHALAN 200 MG/M(2) | - |
dc.subject.keywordPlus | HIGH-DOSE MELPHALAN | - |
dc.subject.keywordPlus | CONDITIONING REGIMENS | - |
dc.subject.keywordPlus | DEXAMETHASONE | - |
dc.subject.keywordPlus | LENALIDOMIDE | - |
dc.subject.keywordPlus | DARATUMUMAB | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordPlus | OLDER | - |
dc.subject.keywordAuthor | Multiple myeloma | - |
dc.subject.keywordAuthor | Autologous | - |
dc.subject.keywordAuthor | Stem cell | - |
dc.subject.keywordAuthor | Transplantation | - |
dc.subject.keywordAuthor | Elderly | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.